Internal records reveal that for years Penn State’s clinical cancer research was mired in deep-rooted and potentially ...

The global syndrome therapeutics market size was valued at US$ 147.4 Mn in 2024 and is projected to reach US$ 407.3 Mn by ...

Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...

Orforglipron is a small‑molecule, nonpeptide GLP‑1 receptor agonist taken once daily, and it skips some of the hassles that ...

Breast Cancer Canada has released its 2025 Annual Progress Report, offering a comprehensive overview of breast cancer care in Canada. The report highlights advances in treatment, screening, and policy ...

For older adults, those with heart disease, or anyone working outdoors, maintaining fluid balance is protective, it helps ...

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics announced the results of its 2025 Annual General Meeting, ...

Drs Joseph Mikhael and Sigurdur Y. Kristinsson discuss whether it is time to screen for multiple myeloma and what we can ...

Azenta ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on ...

Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties : As we prepare to end 2025, we would like to provide you with this open letter summarizing our ...

Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other ...

A review and meta-analysis published in Diabetes Metabolism Research and Reviews has revealed that tirzepatide has a neutral ...